Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Vascular Spasm01:16

Vascular Spasm

The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Understanding the Effect of Transfusion Rates on Differential Modulation of Inflammatory Responses".

The Journal of surgical research·2026
Same author

HS3ST1 regulates pulmonary inflammation and is a determinant of clinical outcomes after trauma and hemorrhagic shock.

bioRxiv : the preprint server for biology·2026
Same author

Donor sex and platelet storage change the therapeutic effects of platelet-derived extracellular vesicles on endothelium.

Blood vessels, thrombosis & hemostasis·2026
Same author

Optimization of platelet-derived extracellular vesicle preparation for hemostatic efficacy during major traumatic hemorrhage.

Shock (Augusta, Ga.)·2026
Same author

Plasma Constituents Promote Endothelial Thromboinflammatory Dysfunction After Hemorrhagic Shock.

Shock (Augusta, Ga.)·2026
Same author

Hyperfibrinolysis in trauma-induced coagulopathy: exploring the role of inflammatory cytokines.

Journal of thrombosis and haemostasis : JTH·2025
Same journal

Investigation of the preanalytical stability of blood donor samples.

Transfusion·2026
Same journal

The need for dried plasma-Still a national issue: Where are we and recommendations.

Transfusion·2026
Same journal

Spray dried plasma manufactured from apheresis and whole blood derived plasma.

Transfusion·2026
Same journal

Identification of a novel ABO*A1.01 allele with c.562C>T (p.Arg188Cys) mutation associated with A<sub>el</sub> phenotype in a Chinese individual.

Transfusion·2026
Same journal

AABB survey on directed blood donation practices.

Transfusion·2026
Same journal

Cost analysis considerations for red blood cell matching to mitigate alloimmunization in patients with sickle cell disease.

Transfusion·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2026

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine
08:27

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine

Published on: December 6, 2024

New hemostatic agents in the combat setting.

E Darrin Cox1, Martin A Schreiber, John McManus

  • 1U.S. Army Institute of Surgical Research, Fort Sam Houston, Texas 78234-6315, USA.

Transfusion
|December 4, 2009
PubMed
Summary
This summary is machine-generated.

New hemostatic bandages like HemCon and QuikClot effectively control trauma-related hemorrhage. While HemCon showed no adverse effects, QuikClot caused superficial burns in some patients, indicating its potential risks.

More Related Videos

Integrated Compensatory Responses in a Human Model of Hemorrhage
07:57

Integrated Compensatory Responses in a Human Model of Hemorrhage

Published on: November 20, 2016

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 18, 2026

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine
08:27

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine

Published on: December 6, 2024

Integrated Compensatory Responses in a Human Model of Hemorrhage
07:57

Integrated Compensatory Responses in a Human Model of Hemorrhage

Published on: November 20, 2016

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

  • Trauma Care
  • Surgical Hemostasis
  • Emergency Medicine

Background:

  • Hemorrhage is a primary cause of preventable death in trauma patients.
  • Hemostatic bandages have demonstrated efficacy in animal models for reducing blood loss and improving survival.
  • This study examines clinical observations of two novel hemostatic bandages used in military settings.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of QuikClot and HemCon hemostatic bandages.
  • To assess the application settings and wound types treated with these hemostatic agents.
  • To report on patient outcomes associated with the use of these bandages.

Main Methods:

  • Retrospective cohort review of soldiers treated with QuikClot or HemCon from April to October 2006.
  • Data collected on dressing application location (field vs. combat support hospital) and wound location (extremity, truncal, pelvic).
  • Analysis of patient outcomes, including hemorrhage control and adverse events.

Main Results:

  • Fifty hemostatic dressing applications were identified in 44 trauma patients.
  • HemCon was used more frequently than QuikClot.
  • In 95% of surviving patients, hemorrhage was significantly reduced or stopped by the hemostatic dressings.
  • Two patients treated with QuikClot experienced exothermic reactions causing superficial burns; no adverse reactions were reported with HemCon.

Conclusions:

  • Hemostatic agents are effective in controlling traumatic hemorrhage.
  • HemCon appears to be a safe hemostatic agent.
  • QuikClot may cause superficial burns, highlighting a potential safety concern.
  • These hemostatic agents are valuable adjuncts in managing internal hemorrhage, particularly in damage-control surgery.